Introduction
In recent years adrenergic ,8-receptor blocking agents have been advocated for prophylactic use in angina pectoris, and several workers have commented on their efficacy in reducing the number of attacks and increasing working capacity (Gillam and Prichard, 1966; Adolfsson and Areskog, 1967; Bjmrntorp, 1967 Bjmrntorp, , 1968 Arstila et al., 1969; Areskog et al., 1969; Sealey et al., 1970) . As angina pectoris is thought to be due to relative myocardial ischaemia when the work-load on the heart is increased, any therapy should aim at improving the balance between oxygen demand and oxygen supply to the myocardium. This can be accomplished by increasing the blood supply through dilatation of the coronary arteries. Even though some parts of the coronary arteries may dilate, however, the sclerosed parts will determine the maximum flow to the perfused area.
Nitroglycerin has a vasodilative effect on coronary vessels and collaterals (McGregor and Fam, 1966) , but most of its action in relieving an acute anginal attack is probably due to venous pooling through direct venular dilatation (Nordenfelt and Westling, 1967) . This constitutes the other mechanism by which the myocardial oxygen balance may be improvedthrough decrease of the oxygen demand. Cardiac work decreases with venous pooling and consequently the myocardium needs less oxygen. Adrenergic 13-receptor blockers also act by decreasing cardiac work, but through other mechanisms-they decrease heart rate, cardiac output, and arterial pressure (Epstein and Braunwald, 1966) . The so-called long-acting coronary vasodilating drugs, of which nitrates form a prominent and widely used group, have been shown to be less effective than nitroglycerin with regard to acute haemodynamic effects, and evidence of a beneficial effect in long-term treatment is equivocal (Charlier, 1961 
Material and Method
Twenty-three outpatients (21 men and two women) with a typical history of angina pectoris for about 4.5 years (range 0-3-15 years) were included in the study. Nitroglycerin sublingually had proved effective in relieving an anginal attack in all patients. Three did not use nitroglycerin because of headache after taking it. The mean age was 56 (range 44-72) years. Eleven patients had previously had a myocardial infarction, 17 were on anticoagulant treatment, two on digitalis, and two on antihypertensive drugs. Mean relative heart volume was 450 (range 265-670) ml./sq.m. All patients had sinus rhythm and all except four had an abnormal resting electrocardiogram (E.C.G.). Some individual anthropometric data of the 21 patients who completed the trial are given in Table I . Before the trial the patients were told that they would receive a new drug which had seemed promising in the treatment of angina pectoris, and that the trial aimed at determining which strength or which composition was most suitable for them. Therefore during the trial they would receive a new composition every fourth week. Neither the patients nor the doctor were to know which composition was being used during the different periods. They were also told that the most suitable composition would be determined on the basis of the daily annotations. This was accepted by the patients and all took part in the trial with interest.
The trial was designed as a double-blind cross-over comparison of alprenolol (100-mg. tablets), pentanitrol (30-mg. tablets), and placebo, after a single-blind starting period of four weeks on placebo. The different drugs were given in random order and all tablets-were identical in taste and appearance. The treatment periods varied between 26 and 31 days, except on two occasions when they were 21 and 23 days. The dosage was always 1 tablet q.i.d., except for the first four days of each period, when it was i fablet q.i.d. At the end of each treatment period the patients came for a check-up, vwhich included general physical examination with blood 'pressure measurements after 10 minIutes' rest and 2 minutes' standing, 12-lead E.C.G., and a standardized questionary on effect and side-effects. The patients were also asked to rate in terms of "worse," "no effect," and "better" the following variables: subjective working capacity, emotional or exertional angina, incidence of emotional stress, severity of attacks, general status compared with pretrial status, and if nitroglycerin had been as effective as before. Side-effects were assessed by asking for 25 specified s m s at each control visit.
Outdoor temperature readings were obtained daily from a weather monitoring station nearby (Kise in Hedmark), where the weather conditions are not significantly different from those in Gj4vik and surroundings.
In the statistical evaluation Wilcoxon's matched-pairs signed-ranks test (one-tailed) and Fisher's exact probability test (Siegel, 1956) were used. The sums of nitroglycerin tablet consumption and daily rating' score have been interpolated or extrapolated to 28 days in all tables and calculations.
Results
One patient had an acute myocardial infarction during the starting placebo period. He was withdrawn from the trial and admitted to hospital. Another did not want did not use nitroglycerin, as it brought about severe headache. These patients were assessed only by means of the subjective daily rating scoring. The nitroglycerin consumption during the three-double-blind periods for the remaining 18 patients and the differences between the periods are shown in Table II . Table IV . The value for the starting placebo period is probably lower than the true value, as it was clear from the first control visit that a few patients had not kept their diaries properly. During the double-blind periods, however, all diaries seemed to be very well kept, except for two pentanitrol periods. The nitroglycerin consumption was 33% lower during alprenolol than during the doubleblind placebo period. To find out whether this effect was equally distributed over the whole period, the differences for l~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Table V . Apparently the effect increased successively. In the fourth week the mean alprenolol figure was about 40% lower than the mean placebo figure.
The answers to the standardized questions concerning effect did not differ significantly for the different kinds of treatment, except for the severity of attacks (Table VI) . On alprenolol, 11 patients had less severe attacks and none had more severe attacks. The corresponding figures for placebo, or pentanitrol, or both, were 10 and 5 respectively. This difference in dist- P<0-025) . No significant changes in ischaemic ST-T changes, P-R interval, or Q-T time were seen during any treatment on resting E.C.G. The product of heart rate, systolic blood pressure, and Q-T time at rest was calculated for each treatment period. The changes from period to period of this so-called RPQ index (modified after Kimura et al., 1967) could not be correlated to the changes in attack rate or subjective score (see discussion below). Nevertheless, the mean value of this RPQ index was lower on alprenolol than on both placebo (P<0-02) and pentanitrol (P<0.02). The blood pressure did not show any significant variations during the whole trial. No apparent orthostatic reactions occurred. The two patients receiving antihypertensive treatment continued without changes during the entire trial period. Seventeen patients had anticoagulant therapy, which did not have to be changed during any treatment period.
Apart from the two patients excluded at the beginning of the trial, already mentioned, no complications were noted. The questioning on side-effects after each treatment period showed that a number of minor symptoms such as dizziness, headache, lassitude, nausea, and gastrointestinal disturbances occurred during all treatment period with no detectable difference between the various forms of treatment.
Discussion
As many controlled clinical trials in angina pectoris, designed in essentially the same way as the present study, have been published during the last few years, it is of interest to discuss the reliability of this method. The assessment of the drug effect on angina by letting the patient keep his own daily record of nitroglycerin consumption, and the subjective feeling, necessitates mentally stable patients of a certain intellectual capacity who have a minimum of other diseases which could mimic true angina pectoris. Moreover, the natural history of angina pectoris being very variable, the patient should have been known to the doctor long enough to permit a conclusion with regard to the variability-that is, the history of angina should not be too short. Though care was taken to select patients with a history of angina pectoris of one year or more, four turned out to have a history of less than eight months (Cases 4, 6, 13, and 18) . Three of these responded poorly to both alprenolol and pentanitrol, which might be due to too large a variability of symptoms, thus concealing a possible drug effect.
If the patient is accustomed to pushing himself to a certain limit of angina, effective treatment will help him to work more before he reaches this limit if he is the kind that likes or has to perform physical exercise. There may thus be no reduction of nitroglycerin consumption nor in the daily severity rating. The means available in this study to evaluate the pointnamely, standard questions at the end of each period-turned out to be too crude. A device for continuous measurement of daily physical activity would perhaps be the most adequate instrument.
The daily rating of severity was assessed by a method recommended by Greiner et al. (1950) (Ablad et al., 1967b) , corresponds fairly well to the mean dose judged to be optimal for propranolol (Gillam and Prichard, 1966) (1969) noticed a larger fall in nitroglycerin consumption than in attack rate. From this they concluded that the severity of the attacks was affected more than the incidence at that dosage, and that a higher dosage is probably needed to reduce appreciably the number of attacks. Other investigators (Bjcrntorp, 1967 (Bjcrntorp, , 1968 Hickie et al, 1970 ), using a dosage of 100 mg. q.i.d., have confirmed this. In the present study a decrease in the severity of the attacks was found in a significantly (P = 0-05) larger number of patients during alprenolol treatment. than during placebo or pentanitrol treatment. In a study by Sealey et al. (1970) time until pain appeared and total working-time were measured in the course of an exercise test on a fixed work-load after intravenous alprenolol.
They found a significant increase of working-time until pain appeared, and also a significant increase in total workingtime, compared with placebo. This also indicates decreased severity of pain after ,B-adrenergic blockade.
The problem of selecting, by means of a simple test, the anginal patients likely to respond to adrenergic ,3-blockade still remains to be solved. The "RPQ index" previously mentioned, which is similar to the tension-time index, was used by Kimura et al. (1967) as a means of differentiation. They found that during work this index decreased for any drug that was found effective by the patient, whether it was a 18-blocker, a long-acting nitrate, or aminophylline. In the present study there were no facilities for determining this at work. There was no direct correlation of the change of this index at rest and the changes in attack rate and daily subjective scoring, though the mean value was lower during alprenolol treatment than in other periods.
Finally, it is of interest to comment on the safety of the drugs used in this trial. No serious complications, such as cardiac failure or bronchospasm, which have been reported during adrenergic 13-blockade (Stephen, 1966) , were noted. This is probably due to the slight 1-receptor stimulating effect present in alprenolol, which prevents 13-receptor activation disappearing completely in any situation. Haemodynamic studies in patients with coronary artery disease (Malers and Soderholm, 1969) as well as in patients with chronic bronchitis (Tivenius and Nyberg, 1970 ) also confirm a significant difference in these respects between alprenolol and propranolol, the only other 13-blocker which has been widely used. As for minor side-effects, none of importance were noted for alprenolol.
